Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Osmotica Pharmaceuticals Plc (OSMT)

Osmotica Pharmaceuticals Plc (OSMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 279,244
  • Shares Outstanding, K 51,521
  • Annual Sales, $ 240,030 K
  • Annual Income, $ -270,900 K
  • 60-Month Beta 3.31
  • Price/Sales 1.17
  • Price/Cash Flow 0.79
  • Price/Book 2.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.22
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.80 +11.46%
on 09/14/20
6.01 -10.98%
on 08/28/20
-0.44 (-7.60%)
since 08/21/20
3-Month
4.80 +11.46%
on 09/14/20
9.67 -44.67%
on 07/10/20
-1.35 (-20.15%)
since 06/22/20
52-Week
2.81 +90.39%
on 04/01/20
9.67 -44.67%
on 07/10/20
+1.64 (+44.20%)
since 09/20/19

Most Recent Stories

More News
Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James "JD" Schaub,...

OSMT : 5.33 (-1.66%)
OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

OSMT : 5.33 (-1.66%)
Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates

Second quarter 2020 total revenue of $37.5 million

OSMT : 5.33 (-1.66%)
Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq(TM) on August 11, 2020

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial...

OSMT : 5.33 (-1.66%)
OSMOTICA PHARM (OSMT) Expected to Beat Earnings Estimates: Should You Buy?

OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OSMT : 5.33 (-1.66%)
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

RGEN : 141.24 (-0.43%)
BMY : 58.17 (+0.69%)
OSMT : 5.33 (-1.66%)
TLSA : 3.51 (-3.04%)
Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher

Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

AKCA : 18.15 (+0.06%)
OSMT : 5.33 (-1.66%)
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James "JD" Schaub,...

OSMT : 5.33 (-1.66%)
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

, /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results of the Company's Annual General Meeting....

OSMT : 5.33 (-1.66%)
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn,...

OSMT : 5.33 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade OSMT with:

Business Summary

Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R)...

See More

Key Turning Points

2nd Resistance Point 5.66
1st Resistance Point 5.54
Last Price 5.33
1st Support Level 5.18
2nd Support Level 4.94

See More

52-Week High 9.67
Fibonacci 61.8% 7.05
Fibonacci 50% 6.24
Fibonacci 38.2% 5.43
Last Price 5.33
52-Week Low 2.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar